BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
latest_posts
- 1
Mom warns of Christmas gift hazard as daughter recovers in hospital - 2Nodding off is dangerous. Some animals have evolved extreme ways to sleep in precarious environments
- 3RFK Jr. succeeds in changing hepatitis B recommendation | The Excerpt
- 4Unraveling the Specialty of Picking Your Ideal Travel Objective
- 5Palestinians tell BBC they were sexually abused in Israeli prisons
- IDF confirms Iranian missile fragments hit near Kirya, multiple cars ablaze in Ramat Gan
- FDA updates risk classification for voluntary shredded cheese recall
- The Solution to Individual budget: Dominating Cash The board
- Are multiverses real? An astrophysicist explains why it depends on how you define ‘real’
- 6 U.S. States for Climbing
- Vote in favor of your Number one Kind of Gems
- Must-See Attractions in Australia
- 6 Exemplary Mexican Dishes
- Feeling wonder every day improves our health. Here’s how to do it.
